Market research
RAPT RAPT Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 58
- Dividend yield
- Not available
- Beta
- 0.44
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US75382E1091
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 58
- Dividend yield
- Not available
- Beta
- 0.44
About
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RAPT discussion.
5 years, 4 months ago
RAPT Therapeutics, Inc is currently in a long term uptrend where the price is trading 41.2% above its 200 day moving average.
From a valuation standpoint, the stock is 91.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 111.2.
RAPT Therapeutics, Inc's total revenue rose by inf% to $1M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-13K since the same quarter in the previous year.
Finally, its free cash flow fell by 172.0% to $-16M since the same quarter in the previous year.
Based on the above factors, RAPT Therapeutics, Inc gets an overall score of 4/5.